Iberdomide Maintenance Therapy Following CAR-T in Multiple Myeloma

What is the Purpose of this Study?

This study focuses on individuals who have multiple myeloma that has relapsed (meaning it has come back after prior therapy) and/or refractory (resistant to certain therapies). The purpose of the study is to determine whether a drug called iberdomide can be given after idecabtagene vicleucel (ide-cel Abecma- CAR T cell therapy) in multiple myeloma safely and with acceptably mild side effects. Researchers also want to know how long multiple myeloma stays under control (in remission) if patients receive the study drug iberdomide after they have received ide-cel CAR T cell therapy. The study will evaluate various doses of iberdomide to determine which dose is safer when used after ide-cel (Abecma) CAR-T. The use of iberdomide in this study is investigational.


Eligibility

  • * PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0):
  • * All patients must be pre-registered in order to submit the required bone marrow and blood specimens
  • * Note: Bone marrow aspirate for patients who consent to biobanking should also be submitted at this time as outlined
Show more

Where can I participate?

Cedars-Sinai Cancer at SOCC : Emilie Douine-Barthelemy

More about this Clinical Trial

What is the full name of this clinical trial?

A062102: Randomized phase 2 study of iberdomide maintenance therapy following idecabtegene vicleucel CAR-T in multiple myeloma

Study Details
Disease Type/Condition

Multiple Myeloma

Principal Investigator

Oveisi, David

Co-Investigators

Akil Merchant, Joshua Sasine, Justin Darrah, Noah Merin, Robert Vescio, Ronald Paquette

Age Group

Adult

Phase

II

IRB Number

STUDY00003449

ClinicalTrials.gov ID

NCT06179888

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Emilie Douine-Barthelemy

Email
emilie.douine-barthelemy@cshs.org
Study Detail
Disease Type/Condition

Multiple Myeloma

Principal Investigator

Oveisi, David

Age Group

Adult

Phase

II

IRB Number

A062102

ClinicalTrials.gov ID

NCT06179888

Key Eligibility
ClinicalTrials.gov

Contact
Name

Emilie Douine-Barthelemy

Email
emilie.douine-barthelemy@cshs.org